Chongqing Fujin Biological Medicine

Chongqing Fujin Biological Medicine is a clinical-stage biotechnology company based in Chongqing, China, dedicated to the development of long-acting protein and peptide therapeutics. The company utilizes proprietary technology platforms to create next-generation treatments for metabolic and endocrine disorders, focusing on improving the pharmacokinetic properties of biologics. Its lead candidate, FJ-002, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently being evaluated for the treatment of obesity and type 2 diabetes. Another key program, FJ-001, is a long-acting recombinant human growth hormone designed to provide a more convenient dosing schedule for patients with growth hormone deficiency. Fujin Biological Medicine aims to bridge the gap between innovative drug delivery science and clinical application to enhance patient compliance and therapeutic outcomes. The company maintains integrated capabilities spanning from research and development to GMP-compliant manufacturing.